Provided by Tiger Fintech (Singapore) Pte. Ltd.

Precision Biosciences Inc

4.75
-0.0495-1.03%
Volume:24.50K
Turnover:118.00K
Market Cap:52.67M
PE:-1.70
High:4.92
Open:4.71
Low:4.70
Close:4.80
Loading ...

Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025

Business Wire
·
20 Mar

Precision Biosciences Price Target Maintained With a $60.00/Share by HC Wainwright & Co.

Dow Jones
·
20 Mar

Precision BioSciences presents preclinical data from PBGENE-DMD program

TIPRANKS
·
19 Mar

Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Business Wire
·
19 Mar

Precision Says its Investigational New Drug Application for Hepatitis B Treatment Gets US FDA's Clearance

MT Newswires Live
·
17 Mar

Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B

Business Wire
·
17 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
14 Mar

Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Business Wire
·
24 Feb

Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate

Benzinga
·
20 Feb

Precision Biosciences Price Target Maintained With a $60.00/Share by HC Wainwright & Co.

Dow Jones
·
20 Feb

BRIEF-Precision Biosciences Announces Initial Safety And Antiviral Activity Of Pbgene-Hbv

Reuters
·
19 Feb

Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial

Business Wire
·
19 Feb